U.S. Markets open in 8 hrs 58 mins

MacroGenics, Inc. (MGNX)

NASDAQ Global Select - NASDAQ Global Select Delayed Price. Currency in USD
Add to watchlist
15.520.00 (0.00%)
At close: 4:00PM EDT
People also watch
FPRXXLRNXNCRKPTIEPZM

MacroGenics, Inc.

9704 Medical Center Drive
Rockville, MD 20850
United States
301-251-5172
http://www.macrogenics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees318

Key Executives

NameTitlePayExercisedAge
Dr. Scott Koenig M.D., Ph.D.Chief Exec. Officer, Pres and Director783.55k1.92M65
Mr. James KarrelsChief Financial Officer, Sr. VP and Sec.457.46k185.2k50
Dr. Ezio Bonvini M.D.Chief Scientific Officer and Sr. VP of Research492.64k632.73k63
Mr. Eric Blasius RisserChief Bus. Officer and Sr. VP of Bus. Devel. & Portfolio Management474.49k37.15k44
Dr. Jon Wigginton M.D.Chief Medical Officer and Sr. VP of Clinical Devel.565.91k1.13M55
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the company’s products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Corporate Governance

MacroGenics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 8. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.